124 related articles for article (PubMed ID: 16904298)
1. Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials.
Skapinakis P; Papatheodorou T; Mavreas V
Eur Neuropsychopharmacol; 2007 Jan; 17(2):79-93. PubMed ID: 16904298
[TBL] [Abstract][Full Text] [Related]
2. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
Erzegovesi S; Guglielmo E; Siliprandi F; Bellodi L
Eur Neuropsychopharmacol; 2005 Jan; 15(1):69-74. PubMed ID: 15572275
[TBL] [Abstract][Full Text] [Related]
3. Use of atypical antipsychotics in refractory depression and anxiety.
Nemeroff CB
J Clin Psychiatry; 2005; 66 Suppl 8():13-21. PubMed ID: 16336032
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.
Dold M; Aigner M; Lanzenberger R; Kasper S
Int J Neuropsychopharmacol; 2015 May; 18(9):. PubMed ID: 25939614
[TBL] [Abstract][Full Text] [Related]
5. [Combination of risperidone and serotonergic antidepressants in refractory obsessive-compulsive disorder].
Salmerón JM; Alcántara AG; Barcia D
Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1998; 26(6):399-402. PubMed ID: 9972593
[TBL] [Abstract][Full Text] [Related]
6. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials.
Dold M; Aigner M; Lanzenberger R; Kasper S
Int J Neuropsychopharmacol; 2013 Apr; 16(3):557-74. PubMed ID: 22932229
[TBL] [Abstract][Full Text] [Related]
7. Augmentation of standard antidepressants with atypical antipsychotic agents for treatment-resistant major depressive disorder.
Papakostas GI
Essent Psychopharmacol; 2005; 6(4):209-20. PubMed ID: 16041917
[TBL] [Abstract][Full Text] [Related]
8. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
Goodwin G; Fleischhacker W; Arango C; Baumann P; Davidson M; de Hert M; Falkai P; Kapur S; Leucht S; Licht R; Naber D; O'Keane V; Papakostas G; Vieta E; Zohar J
Eur Neuropsychopharmacol; 2009 Jul; 19(7):520-32. PubMed ID: 19411165
[TBL] [Abstract][Full Text] [Related]
9. Augmentation of clozapine with a second antipsychotic--a meta-analysis of randomized, placebo-controlled studies.
Taylor DM; Smith L
Acta Psychiatr Scand; 2009 Jun; 119(6):419-25. PubMed ID: 19245679
[TBL] [Abstract][Full Text] [Related]
10. [Is it time for revision of the section on obsessive-compulsive disorder in the Guideline on Anxiety Disorders?].
van Ingen Schenau WJ; Wisman PW
Tijdschr Psychiatr; 2007; 49(5):315-25. PubMed ID: 17492582
[TBL] [Abstract][Full Text] [Related]
11. Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: effectiveness for depression and anger symptoms.
Mercer D; Douglass AB; Links PS
J Pers Disord; 2009 Apr; 23(2):156-74. PubMed ID: 19379093
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of randomized, controlled treatment trials for pediatric obsessive-compulsive disorder.
Watson HJ; Rees CS
J Child Psychol Psychiatry; 2008 May; 49(5):489-98. PubMed ID: 18400058
[TBL] [Abstract][Full Text] [Related]
13. Treatments for late-life bipolar disorder.
Aziz R; Lorberg B; Tampi RR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):347-64. PubMed ID: 17296540
[TBL] [Abstract][Full Text] [Related]
14. Augmentation of antidepressants with perospirone for treatment-resistant major depressive disorder.
Sato Y; Yasui-Furukori N; Nakagami T; Saito M; Kaneko S
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Apr; 33(3):416-8. PubMed ID: 19166896
[TBL] [Abstract][Full Text] [Related]
15. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder.
Storch EA; Merlo LJ; Bengtson M; Murphy TK; Lewis MH; Yang MC; Jacob ML; Larson M; Hirsh A; Fernandez M; Geffken GR; Goodman WK
Int Clin Psychopharmacol; 2007 Jul; 22(4):230-7. PubMed ID: 17519647
[TBL] [Abstract][Full Text] [Related]
16. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
17. Drug treatment of obsessive-compulsive disorder: a review of findings in the light of diagnostic and metric limitations.
Towbin KE; Leckman JF; Cohen DJ
Psychiatr Dev; 1987; 5(1):25-50. PubMed ID: 2885832
[TBL] [Abstract][Full Text] [Related]
18. Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol.
Sa AR; Hounie AG; Sampaio AS; Arrais J; Miguel EC; Elkis H
Compr Psychiatry; 2009; 50(5):437-42. PubMed ID: 19683614
[TBL] [Abstract][Full Text] [Related]
19. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
Houthoofd SA; Morrens M; Sabbe BG
Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
[TBL] [Abstract][Full Text] [Related]
20. Perospirone augmentation of paroxetine in treatment of refractory obsessive-compulsive disorder with depression.
Otsuka T; Togo T; Sugiyama N; Uehara K; Yoshimi A; Karashima A; Shioya H; Hirayasu Y
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):564-6. PubMed ID: 17166643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
